Hemorrhagic complications in pediatric hematologic malignancies

Seminars in Thrombosis and Hemostasis

Volumn 33, Issue 4, 2007, Pages 408-415

  Athale, Uma H ^a   Chan, Anthony K C ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Hemorrhage; Leukemia; Lymphoma; Pediatric; Platelet transfusion

Indexed keywords

BLOOD CLOTTING FACTOR 7A; FIBRINOGEN;

BLEEDING; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; CANCER SURVIVAL; CHILDHOOD CANCER; DISEASE PREDISPOSITION; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE UTILIZATION; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; INFECTION; LEUKEMIA; LEUKOCYTOSIS; LUNG HEMORRHAGE; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

CHILD; DISEASE MANAGEMENT; HEMATOLOGIC NEOPLASMS; HEMORRHAGE; HUMANS; RISK FACTORS;

EID: 34249944181     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-976176     Document Type: Review

References (49)

1. Canada NCI. Canadian Cancer Statistics. Toronto: NCI; 69-71
2. Smith M. Childhood cancer: Incidence, survival, and mortality. In: Pizzo P, ed. Principles and Practice of Pediatric Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:1-12
3. Sandlund JT, Downing JR, Crist WM. Non-Hodgkin's lymphoma in childhood. N Engl J Med 1996;334:1238-1248
4. Slats AM, Egeler RM, van der Does-van den Berg A, et al. Causes of death - other than progressive leukemia - in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia 2005;19:537-544
5. Brenner B, Hoffman R, Balashov D, Shutluko E, Culic SD, Nizamoutdinova E. Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII. Clin Appl Thromb Hemost 2005;11:401-410
6. Rubnitz JE, Lensing S, Zhou Y, et al. Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience. Cancer 2004;101:1677-1684
7. Wheeler K, Chessells JM, Bailey CC, Richards SM. Treatment related deaths during induction and in first remission in acute lymphoblastic leukaemia: MRC UKALL X. Arch Dis Child 1996;74:101-107
8. Liang DC, Hung IJ, Yang CP, et al. Unexpected mortality from the use of E. coli L-asparaginase during remission induction therapy for childhood acute lymphoblastic leukemia: a report from the Taiwan Pediatric Oncology Group. Leukemia 1999;13:155-160
9. Riley LC, Hann IM, Wheatley K, Stevens RF. Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10). The MCR Childhood Leukaemia Working Party. Br J Haematol 1999;106:436-444
10. Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004;22:4384-4393
11. Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005;19: 2030-2042
12. O'Brien TA, Russell SJ, Vowels MR, et al. Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group. Blood 2002;100:2708-2716
13. Clavell LA, Gelber RD, Cohen HJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 1986;315:657-663
14. Ribeiro RC, Pui CH. The clinical and biological correlates of coagulopathy in children with acute leukemia. J Clin Oncol 1986;4:1212-1218
15. Wermes C, von Depka Prondzinski M, Lichtinghagen R, Barthels M, Welte K, Sykora KW. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr 1999; 158(suppl 3):S143-S146
16. Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood 1996;87:4979-4989
17. Kim H, Lee JH, Choi SJ, Kim WK, Lee JS, Lee KH. Analysis of fatal intracranial hemorrhage in 792 acute leukemia patients. Haematologica 2004;89:622-624
18. Goad KE, Gralnick HR. Coagulation disorders in cancer. Hematol Oncol Clin North Am 1996;10:457-484
19. Wilde JT, Davies JM. Haemostatic problems in acute leukaemia. Blood Rev 1990;4:245-251
20. Quinones-Hinojosa A, Gulati M, Singh V, Lawton MT. Spontaneous intracerebral hemorrhage due to coagulation disorders. Neurosurg Focus 2003;15:1-15
21. Kyrnetskiy EE, Kun LE, Boop FA, Sanford RA, Khan RB. Types, causes, and outcome of intracranial hemorrhage in children with cancer. J Neurosurg 2005;102:31-35
22. Ott N, Ramsay NK, Priest JR, et al. Sequelae of thrombotic or hemorrhagic complications following L-asparaginase therapy for childhood lymphoblastic leukemia. Am J Pediatr Hematol Oncol 1988;10:191-195
23. Soylu AR, Buyukasik Y, Cetiner D, et al. Overt gastrointestinal bleeding in haematologic neoplasms. Dig Liver Dis 2005;37:917-922
24. Schwartz JM, Wolford JL, Thornquist MD, et al. Severe gastrointestinal bleeding after hematopoietic cell transplantation, 1987-1997: incidence, causes, and outcome. Am J Gastroenterol 2001;96:385-393
25. Jackson N, Reddy SC, Hishamuddin M, Low HC. Retinal findings in adult leukaemia: correlation with leukocytosis. Clin Lab Haematol 1996;18:105-109
26. Reddy SC, Quah SH, Low HC, Jackson N. Prognostic significance of retinopathy at presentation in adult acute leukemia. Ann Hematol 1998;76:15-18
27. Reddy SC, Menon BS. A prospective study of ocular manifestations in childhood acute leukaemia. Acta Ophthalmol Scand 1998;76:700-703
28. Reddy SC, Jackson N. Retinopathy in acute leukaemia at initial diagnosis: correlation of fundus lesions and haematological parameters. Acta Ophthalmol Scand 2004;82:81-85
29. Rogers Z. Hematologic supportive care. In: Pizzo P, ed. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott Williams & Wilkins; 2002:1205-1238
30. Wehmeier A, Sudhoff T, Meierkord F. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders. Semin Thromb Hemost 1997; 23:391-402
31. Behm F. Manifestations of the bone marrow. In: Parham D, ed. Pediatric Neoplasia: Morphology and Biology. Philadelphia: Lippincott-Raven; 1996:449-504
32. Falanga A, Barbui T. Coagulopathy of acute promyelocytic leukemia. Acta Haematol 2001;106:43-51
33. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002;100:4298-4302
34. Ucar C, Caliskan U. Successful treatment of acute lymphoblastic leukemia with L-asparaginase-induced intracranial hemorrhage to activated recombinant factor VIIa in a child. Pediatr Hematol Oncol 2006;23:339-345
35. Sanz MA. Treatment of acute promyelocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2006:147-155
36. Gmur J, Burger J, Schanz U, Fehr J, Schaffner A. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 1991;338:1223-1226
37. Callow CR, Swindell R, Randall W, Chopra R. The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy. Br J Haematol 2002;118:677-682
38. Gil-Fernandez JJ, Alegre A, Fernandez-Villalta MJ, et al. Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution. Bone Marrow Transplant 1996;18:931-935
39. Heckman KD, Weiner GJ, Davis CS, Strauss RG, Jones MP, Burns CP. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. J Clin Oncol 1997;15:1143-1149
40. Howard SC, Gajjar AJ, Cheng C, et al. Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia. JAMA 2002;288:2001-2007
41. Vavricka SR, Walter RB, Irani S, Halter J, Schanz U. Safety of lumbar puncture for adults with acute leukemia and restrictive prophylactic platelet transfusion. Ann Hematol 2003;82:570-573
42. Howard SC, Gajjar A, Ribeiro RC, et al. Safety of lumbar puncture for children with acute lymphoblastic leukemia and thrombocytopenia. JAMA 2000;284:2222-2224
43. Priest JR, Ramsay NK, Bennett AJ, Krivit W, Edson JR. The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia. J Pediatr 1982;100:990-995
44. Legnani C, Palareti G, Pession A, et al. Intravascular coagulation phenomena associated with prevalent fall in fibrinogen and plasminogen during L-asparaginase treatment in leukemic children. Haemostasis 1988;18:179-186
45. Ramsay NK, Coccia PF, Krivit W, Nesbit ME, Edson JR. The effect of L-asparaginase of plasma coagulation factors in acute lymphoblastic leukemia. Cancer 1977;40:1398-1401
46. Homans AC, Rybak ME, Baglini RL, Tiarks C, Steiner ME, Forman EN. Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia. J Clin Oncol 1987;5:811-817
47. Halton JM, Mitchell LG, Vegh P, Eves M, Andrew ME. Fresh frozen plasma has no beneficial effect on the hemostatic system in children receiving L-asparaginase. Am J Hematol 1994;47:157-161
48. Nowak-Gottl U, Rath B, Binder M, et al. Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy. Haematologica 1995;80:451-453
49. Das P, Carcao M, Hitzler J. Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia. Pediatr Blood Cancer 2006;47:206-209